A pill version of the popular GLP-1 weight-loss drug Wegovy has been green-lit for use in the U.S. Here’s what that means for ...

The Wegovy pill is one of two oral GLP-1 drugs expected to hit the market in the next few months; the other, from Lilly, is called orforglipron – until it receives a brand name – and is expected to be ...

The FDA has approved the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for weight loss and to reduce the risk ...

Popular weight loss drugs like Ozempic and Wegovy work by artificially increasing levels of a natural anti-obesity/anti-diabetes hormone called glucagon-like peptide 1 (GLP-1). Can we reap its ...

Bariatric doctors who regularly prescribe GLP-1s share how long the worst Ozempic side effects last, and the best ways to ...

GLP-1 drugs like Ozempic and Wegovy have rapidly moved from niche diabetes treatments to blockbuster weight loss injections, reshaping how doctors and patients think about obesity. As prescriptions ...

Oral weight-loss pills will be replacing GLP-1 shots by March 2026, Medicare and Medicaid Services Administrator Dr. Mehmet Oz predicted on Monday. Oz made the statement during a Monday morning ...

In this video, Mikhail Varshavski, DO, who goes by "Dr. Mike," talks with Christle Guevarra, DO, MS, about her struggle with weight, her journey with GLP-1 drugs, and her career in medicine.

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Eli Lilly announced Phase 3 trials results for its daily, oral GLP-1 drug. Drugmaker Eli Lilly says its oral, daily GLP-1 pill may offer similar weight loss results as weekly GLP-1 shots. Eli Lilly, ...

The investigational GLP-1 receptor agonist MET-097i, which may be able to be dosed just once a month, yielded weight loss of up to 14.1% by week 28 with class-leading tolerability in a phase IIb trial ...